HIGHLIGHTS
- who: Ilias B. Esmagambetov from the National Institute of Health (ISS), Italy Northern Arizona University have published the paper: rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis, in the Journal: (JOURNAL)
- what: The authors focused on antibody delivery using a recombinant adeno-associated virus (rAAV) (Bulcha et_al, 2021). rAAV are the most promising delivery vehicles due to their non-pathogenic properties, lack of immunogenicity, and inability to integrate into the genome, as well as long-term persistence in the body (Nieto and Salvetti, 2014). The authors used a recombinant adeno-associated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.